https://www.selleckchem.com/products/GDC-0449.html
CONCLUSIONS mTOR inhibitors, at therapeutic levels, directly activate polyomavirus replication through a Skp2-dependent mechanism, revealing a proteostatic latency mechanism common to polyomaviruses. Modifying existing drug regimens for transplant patients with polyomavirus-associated diseases may reduce symptomatic polyomavirus replication while maintaining allograft-sparing immune suppression. immunosuppression. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.BACKGROUND Glutam
Like
Comment
Share
